Minimizing protocol deviations is a simple, yet effective way for sites to keep trials patient-centric.
Bayesian methods bring flexibility and speed to clinical trial design and analysis, and with increased access to the necessary computational power, are transforming today’s clinical research.
While the world focuses on COVID-19, this article provides insight on the current state of the market for antimicrobial resistant (AMR) medicines.
An overview of the advantages of implementing AI into clinical development and the obstacles that prevent its widespread adoption.
It is unrealistic to include infinite adaptations in an IRT system, thus identifying the optimal level of adaptations requires examination of the study’s characteristics and planning phase considerations.
A discussion of how the coronavirus pandemic will have a multitude of impacts on the conduct of trials, as well as on the industry itself.
Companies that understand the regulatory environment in Europe can keep their trials on budget and on schedule.
All stakeholders must play part in increasing implementation.
The clinical research industry is increasingly leveraging insights, experience, and advanced solutions to better implement diversity and inclusion initiatives.
From design and trial start-up to conduct and analysis, there is enormous potential for applications of artificial intelligence within clinical trials to have a profound impact on human health.
Exploring the implications of FDA’s renewed focus and commitment to expand the use of accelerated approval for gene therapy products.
Practical ways CROs and sponsors can support sites and improve quality.
Strategies and considerations for adopting decentralized clinical trials.
Allucent’s Katy Moore, Pharm. D., R.Ph. President, Clinical Pharmacology Modeling and Simulation, offers insightful commentary for small and mid-sized biotechs developing scientific breakthroughs. Learn from Katy’s expertise how applying modeling and simulation can improve drug development and help bring new therapies to light.
Examining how to optimizing the time and effort of Ethics Committees to efficiently and effectively fulfill their human subjects protection remit.
Survey examines trial enrollment motivation among diverse populations.
To optimize the Sponsor/CRO relationship, the final proposal must represent a win for both parties.
Laboratory services organization focuses on easing patient and site burden with improved collection device.
The four new methodological Patient-Focused Drug Development guidance documents the FDA is currently developing for the industry that incorporate patient experience data into drug development, summarized.
Regulatory compliance, collaboration, and effective use of technology among ways CROs can overcome challenges.
With close collaboration between sponsors, CROs, and regulators, this emerging technology has the potential to greatly improve the lives of patients.
Wearable digital health technologies can enhance traditional clinical outcome assessments, such as for neurology, pulmonology, cardiology, and rheumatology.
Patient insights are expected to become increasingly instrumental in optimizing medicine development and regulatory decision-making.
New online platform, Clinical Trial Guide seeks to improve access.
Recognizing pre-pandemic pain points, such as patient engagement and protocol development, could lead to post-pandemic trial success.
Testing in humans in clinical trials and the regulatory approval process itself are candidates for technology solutions where artificial intelligence is playing a role.
Common advice for OA sufferers is joint replacement, but other options are on the horizon.
Study seeks to understand how different forms of data meet the needs of researchers.